Latest Regulation News

Sexual Services in Australia Industry Market Research Report now updated by IBISWorldHistorically, prostitutes have experienced a steady level of demand, almost irrespective of economic conditions, to the point that the industry has been labelled ‘recession proof' by some. In the past, this has often been the case. However, alternatives to the industry’s services such as websites, pornography and other cheaper substitutes have gained popularity and have negatively affecte...

Regulation of TH2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cellsIn lymph nodes, cellular positioning can dictate the immune response. Lund and colleagues show that nematode infection triggers interactions between lymphotoxin-producing B cells and CXCR5+ dendritic cells and CD4+ T cells to initiate T helper type 2...

House to vote on PDUFA bill next weekThe U.S. House of Representatives will vote on its version of PDUFA reauthorization legislation next Wednesday, according to a memo sent to House Republicans by Majority Leader Eric Cantor (R-Va.). Cantor hopes to reach an agreement with the Senate b...

Health Net Announces Appearance at Sanford C. Bernstein’s 28th Strategic Decisions ConferenceHealth Net, Inc. (NYSE:HNT) today announced that members of its management team are scheduled to present at Sanford C. Bernstein’s 28th Strategic Decisions Conference on May 30, 2012, at approximately 9:00 a.m. Eastern time. A live webcast and replay of the presentation will be available at www.healthnet.com under “

Albemarle to increase ibuprofen pricesBATON ROUGE, La., May 25, 2012 /PRNewswire/ -- Albemarle Corporation (NYSE: ALB), a global developer, manufacturer and marketer of highly engineered specialty chemicals, announced today that it will increase global prices for all grades of ibuprofen by an estimated 15% effective immediately, or as contracts allow. (Logo: http://photos.prnewswire.com/prnh/20111129/MM14279LOGO ) Albema...

Novo Nordisk receives positive opinion on recombinant factor XIII from the European regulatory ...

China Drafts Rule To Ban Import Of Devices Without Chinese LabelsChina’s State FDA considers a draft regulation that would prohibit imports of medical devices without Chinese labels.

MDxHealth: Annual and Extraordinary General Shareholders’ MeetingRegulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Annual and Extraordinary General Meeting of shareholders in Zaventem today. The shareholders approved all agenda items of the Annual General Meeting, including th...

APPG reports on drug shortages and MHRA bans unlicensed stock tradingOn 14 May 2012, the All-Party Pharmacy Group (APPG) published the results of its inquiry into drug shortages in the UK. In response to this the Medicines and Healthcare products Regulatory Agency (MHRA) has decided to ban unlicensed stock trading by...

World Biosimilars Congress 2012Strategies for navigating the regulatory, manufacturing, sales and marketing route to biosimilars market entry

Current pharma pricing policy will hurt both patients and industry in the long run, assert pharma expertsPharmaceutical analysts in India and the UK believe cost-based pricing is not suitable to safeguard the interests of patients as well as the pharmaceutical industry. In their opinion, the regulatory authorities have wrongly been focusing on price con...

EU regulators give positive opinion on Novo Nordisk factor XIII productCOPENHAGEN, May 25 (Reuters) - Danish drug maker Novo Nordisk said on Friday it had received a positive opinion on its recombinant factor XIII product from European regulatory authorities.

FDA Small Business Regulatory Education for Industry (REdi) Conference Spring 201219 - 20 June 2012 Conference Westin O\'Hare, Rosemont, IL, US

U.K. agency opposes EU proposal for premarket device reviewThe U.K.'s Medicines and Healthcare products Regulatory Agency said it opposes a proposal to subject certain high-risk medica -More-

Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory BoardCRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its n...

Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & SullivanLONDON, May 25, 2012 /PRNewswire/ -- Increasingly, big pharma is viewing the outsourcing of pharmaceutical manufacturing as a strategic move that would enable them to focus on their core competencies such as R&D. At the same time, the patent expiry of key blockbuster drugs worth $45 billion and biologics worth $30 billion is expected to reduce the capacity utilisation rates of their manuf...

[News] FDA provides fastest drug approvalThe US Food and Drug Administration (FDA) was faster than both the European Medicines Agency (EMA) and Health Canada in the review of applications for novel treatment agents approved between 2001 and 2010. A recent report compared the time taken for...

Physicians protest coming regulatory onslaughtYou and other physicians likely will face a bureaucratic "perfect storm" next year: deadlines for ICD-10 transition, e-prescribing, electronic health records, and the Physician Quality Reporting System-along with a reduction in Medica...

Colgate Bids To Expand U.S. Toothpaste Lineup Through FDA RulemakingColgate seeks regulatory approval for a version of its Colgate Sensitive Multi-Protection toothpaste in a formulation it already markets internationally. The request made in a citizen petition comes after Colgate’s plan to expand its U.S. toothpast...

UPDATE 1-U.S. Senate passes bipartisan FDA funding billWASHINGTON, May 24 (Reuters) - The U.S. Senate on Thursday showed near-unanimous support for a bill that helps fund the U.S. Food and Drug Administration, a regulatory powerhouse with sweeping influence over the foods Americans eat and the medicines...

Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovion's Brovana® ProductPITTSBURGH, May 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into an agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., to resolve the parties' patent litigation relating to Sunovion's Brovana® product. The U.S. District Court for the Southern District of New York's Final Judgment and Or...

The let-7–Imp axis regulates ageing of the Drosophila testis stem-cell nicheIn the Drosophila testis, IGF-II messenger RNA binding protein (Imp) is shown to promote stem-cell niche maintenance by stabilizing unpaired (upd) RNA; Imp levels decrease in the hub cells of older males, owing to regulation by the microRNA let-7.

Paragon Solutions Receives Two Partner Innovation Awards from EMCParagon Solutions, an advisory consulting and systems integration firm, announced today that it was selected for two Partner Innovation Awards from the EMC Information Intelligence Group (IIG) during EMC World. The awards recognized two of Paragon’s solution offerings built on the EMC product suite, one in the area of Pervasive Governance and the other i...

U.S. Senate passes bipartisan FDA funding billWASHINGTON, May 24 (Reuters) - The U.S. Senate on Thursday showed near unanimous support for a bill that helps fund the U.S. Food and Drug Administration, a regulatory powerhouse with sweeping influence over the foods Americans eat and the medicines...

Tekni-Plex, Inc. Announces Closing of $485 Million Senior Secured Notes OfferingKING OF PRUSSIA, Pa., May 24, 2012 /PRNewswire/ -- Tekni-Plex, Inc. (the "Company") announced today the closing of its offering of $485 million aggregate principal amount of 9.750% Senior Secured Notes due 2019 (the "Notes"). The Company sold $485 million aggregate principal amount of the Notes at a price of 98.756% of the par value. The Notes are guaranteed by certain o...

0 1 2 3 4 ›»

buy Regulation market research data and corporate reports now Advertisement